Following research at Imperial College, we believe we’ve found a novel and effective treatment for relapsed/resistant cancer, targeting and killing cancer stem cells. With patents in place, we now need funding for the next phase: to complete lab-testing prior to clinical trials.

  • Novel and proprietary cancer treatment for relapsed/resistant cancer
  • Can kill cancer stem cells, one of the engines of cancer resistance and relapse
  • Strong scientific foundation developed at Imperial College, London
  • Commercially-experienced team with deep oncology knowledge


Cancer is a major cause of death, killing 9.6m people in 2018. We are developing a human protein-based therapeutic product, Syntana-4 (S-4), which inhibits cancer stem cells (CSC) - the growth engine of cancer.

If clinical trials are successful, S-4 could provide a desperately needed treatment option for many relapsed/resistant tumours with ‘Notch’ mutations.

The global cancer drug market was at ~$200bn in 2019. S-4 would initially target use for patients with relapsed prostate cancer, which caused 3.8% of global cancer deaths in 2018. Our research indicates that S-4 could help provide a solution to combat this deadly disease.

Alongside this, our research suggests S-4 will have low manufacturing costs, making it affordable, enabling ‘mass market’ sales strategy.

We have secured the rights and patents related to the delivery platform for CSC and other tissue, based on a cell-penetrating protein (ANTP) which can deliver drugs into the nucleus of cells.

We have raised £450k in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award and are now looking to raise to progress S-4 in collaboration with the University of Chicago’s current cancer stem cell therapeutics R&D program (partnership is pending signature).

Key milestones are to complete all steps to a phase II clinical trial, demonstrate clinical efficacy and then secure an exit through M&A.


The core team:

Prof. Agamemnon Epenetos, Chairman and Chief Executive Officer

He is a successful biotechnology entrepreneur and qualified medical oncologist who has previously developed new drugs through to commercial production.

Mr. Laurence Cohen, Part-time Company Secretary and Director

Solicitor, formerly a Global Head of IP at Latham & Watkins, with expertise in legal, IPR, corporate governance and fund raising logistics. Consultant to a funding introducer for Phase 2 clinical trials.

Dr. Mahendra Deonarain, Part-time Chief Operating Officer

Oversees research and development, financial and logistical activities of the Company. He is involved in successful biotech start-ups and is a director of a commercial R&D laboratory.

Prof. Raymond Moellering, Part-time Chief Scientific Officer

Brings expertise on protein chemistry research and development.

Matthew Cohen, Part-time

Qualified Accountant with M&A and investor relations experience in a FTSE 100 company.

The team is highly diverse and experienced, with a balance of scientific, medical and business skills. They have the requisite skills and expertise to successfully implement the Company’s plans through to commercial fruition.

Anastasis was set up from pioneering R&D at Imperial College. The team are motivated to produce an effective cancer treatment for the benefit of society as a whole.